Acute Myeloid Leukemia Therapeutics Market Assessment 2017-2021

Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage.

Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine kinase inhibitors, and others. Cerubidine (daunorubicin), Adriamycin (doxorubicin), Idamycin (idarubicin) and Cytosar (cytarabine) are currently approved drugs in the acute myeloid leukemia market. Clenegen has a strong pipeline for acute mueloid leukemia. CC-486 is currently in phase 3, durvalumaba is currently in phase 2 trials for treatment of acute mueloid leukemia. ImmunoGen, Inc. is also conducting phase 1 trials for IMGN779. Seattle Genetics? SGN-CD33A is also in phase 3 trials for treatment of AML. In 2016, Jazz Pharmaceutical announced initiation of NDA submission for Vyxeos (cytarabine and daunorubicin liposome injection) or CPX-351. The drug was granted breakthrough designation in 2016 for treatment of adults with AML. Vyxeos was also granted orphan drug status by the U.S. FDA and the European Commission for the treatment of acute myeloid leukemia. With these new additions, the acute myeloid leukemia market would grow rapidly in the future.

Request Free Report Sample@ http://www.sa-brc.com/Global-Acute-Myeloid-Leukemia-Therapeutics-Market-Assessment--Forecast-2017-2021/up96

According to statistics published by the Leukemia & Lymphoma Society (LLS), more than 60,000 were expected to be diagnosed with leukemia, of which over 24,000 would die due to the cancer. Cancer Research U.K. estimates more than 9,000 new cases of leukemia in U.K., which accounts for 3% of all cancer cases. The institute also states that the incidence rate has increased by 15% since the early 1990s. The cancer is more prevalent in elderly as compared to young age. Hence with global aging population, it is expected that the prevalence would increase considerably in the future. This would directly result in increased need of therapeutic drugs, potentially driving the acute myeloid leukemia therapeutics market.

Advancing medical technology with deeper insights to cancer genomics has led to cognizance of key biomarkers that play important role in cancer development and progression. With this understanding, scientists have been able to develop targeted therapy that has revolutionized acute myeloid leukemia therapeutics market. These tests guide in selecting most appropriate therapeutic regimen.

Go For Report TOC@ http://www.sa-brc.com/Global-Acute-Myeloid-Leukemia-Therapeutics-Market-Assessment--Forecast-2017-2021/upcomingdetail96

Key players in the acute myeloid leukemia therapeutics market include GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Biogen Idec, Pfizer Inc. and others.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.